Home » Viragen Reports Peptide Agreement Expired
Viragen Reports Peptide Agreement Expired
Viragen announced that it has elected not to exercise an exclusive option to
license VG104, the IEP 11 peptide, from the University of Miami. The IEP 11
peptide was being researched as a potential cancer therapeutic. In light of
Viragen's decision, the option has expired and all development activities relating
to VG104 have been discontinued.
PharmaLive
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May